Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2020

01-12-2020 | Antibiotic | Research

European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria

Authors: Alain Lepape, Astrid Jean, Jan De Waele, Arnaud Friggeri, Anne Savey, Philippe Vanhems, Marie Paule Gustin, Dominique L. Monnet, José Garnacho-Montero, Anke Kohlenberg

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Background

Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians’ perception of the AMR situation in the European Union/European Economic Area (EU/EEA).

Methods

Between May and July 2017, physicians working in European ICUs were invited to complete an online questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of AMR in the respondent’s ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into the four sub-regions of Eastern, Northern, Southern and Western Europe.

Results

Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by 391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and vancomycin-resistant enterococci. Perception of the relevance of the AMR problem and the frequency of specific MDR bacteria varied by European sub-region. Bacteria resistant to all or almost all available antibiotics were encountered by 132 (12.4%) respondents. Many physicians reported not having access to specific last-line antibiotics.

Conclusions

The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kollef MH, Bassetti M, Francois B, Burnham J, Dimopoulos G, Garnacho-Montero J, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017 Sep;43(9):1187–97.CrossRef Kollef MH, Bassetti M, Francois B, Burnham J, Dimopoulos G, Garnacho-Montero J, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017 Sep;43(9):1187–97.CrossRef
4.
go back to reference Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009. Euro Surveill. 2009;14(45). Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009. Euro Surveill. 2009;14(45).
6.
go back to reference Penalva G, Diaz Högberg L, Weist K, Vlahovic-Palcevski V, Heuer O, Monnet DL, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24(46). Penalva G, Diaz Högberg L, Weist K, Vlahovic-Palcevski V, Heuer O, Monnet DL, et al. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. Euro Surveill. 2019;24(46).
8.
go back to reference David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S,et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4(11):1919–1929.CrossRef David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S,et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4(11):1919–1929.CrossRef
10.
go back to reference Hansen S, Zingg W, Ahmad R, Kyratsis Y, Behnke M, Schwab F, et al. Organization of infection control in European hospitals. J Hosp Infect. 2015;91(4):338–45.CrossRef Hansen S, Zingg W, Ahmad R, Kyratsis Y, Behnke M, Schwab F, et al. Organization of infection control in European hospitals. J Hosp Infect. 2015;91(4):338–45.CrossRef
12.
go back to reference Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47.CrossRef Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47.CrossRef
13.
go back to reference Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the clinical and laboratory standards institute. Clin Infect Dis. 2007;44(6):867–73.CrossRef Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the clinical and laboratory standards institute. Clin Infect Dis. 2007;44(6):867–73.CrossRef
14.
go back to reference Pulcini C, Beovic B, Beraud G, Carlet J, Cars O, Howard P, et al. Ensuring universal access to old antibiotics: a critical but neglected priority. Clin Microbiol Infect. 2017;23(9):590–2.CrossRef Pulcini C, Beovic B, Beraud G, Carlet J, Cars O, Howard P, et al. Ensuring universal access to old antibiotics: a critical but neglected priority. Clin Microbiol Infect. 2017;23(9):590–2.CrossRef
15.
go back to reference Pulcini C, Bush K, Craig WA, Frimodt-Moller N, Grayson ML, Mouton JW, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis. 2012;54(2):268–74.CrossRef Pulcini C, Bush K, Craig WA, Frimodt-Moller N, Grayson ML, Mouton JW, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis. 2012;54(2):268–74.CrossRef
16.
go back to reference Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.CrossRef Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.CrossRef
19.
go back to reference Poulakou G, Matthaiou DK, Bassetti M, Erdem H, Dimopoulos G, Curcio DJ, et al. "Salvage treatment" for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Med. 2017;43(8):1164–6.CrossRef Poulakou G, Matthaiou DK, Bassetti M, Erdem H, Dimopoulos G, Curcio DJ, et al. "Salvage treatment" for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Med. 2017;43(8):1164–6.CrossRef
20.
go back to reference Pulcini C, Williams F, Molinari N, Davey P, Nathwani D. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2011;17(1):80–7.CrossRef Pulcini C, Williams F, Molinari N, Davey P, Nathwani D. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2011;17(1):80–7.CrossRef
21.
go back to reference Zhou JJ, Patel SJ, Jia H, Weisenberg SA, Furuya EY, Kubin CJ, et al. Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units. Infect Control Hosp Epidemiol. 2013;34(3):274–83.CrossRef Zhou JJ, Patel SJ, Jia H, Weisenberg SA, Furuya EY, Kubin CJ, et al. Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units. Infect Control Hosp Epidemiol. 2013;34(3):274–83.CrossRef
22.
go back to reference Bassetti M, De Gaudio R, Mazzei T, Morace G, Petrosillo N, Viale P, et al. A survey on infection management practices in Italian ICUs. Crit Care. 2012;16(6):R221.CrossRef Bassetti M, De Gaudio R, Mazzei T, Morace G, Petrosillo N, Viale P, et al. A survey on infection management practices in Italian ICUs. Crit Care. 2012;16(6):R221.CrossRef
23.
go back to reference Pano-Pardo JR, Schuffelmann-Gutierrez C, Escosa-Garcia L, Laplaza-Gonzalez M, Moreno-Ramos F, Gomez-Gil R, et al. Opportunities to improve antimicrobial use in paediatric intensive care units: a nationwide survey in Spain. Clin Microbiol Infect. 2016;22(2):171–7.CrossRef Pano-Pardo JR, Schuffelmann-Gutierrez C, Escosa-Garcia L, Laplaza-Gonzalez M, Moreno-Ramos F, Gomez-Gil R, et al. Opportunities to improve antimicrobial use in paediatric intensive care units: a nationwide survey in Spain. Clin Microbiol Infect. 2016;22(2):171–7.CrossRef
24.
go back to reference Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J, et al. Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resist. 2013;1(3):131–4.CrossRef Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J, et al. Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resist. 2013;1(3):131–4.CrossRef
25.
go back to reference Rello J, Kalwaje Eshwara V, Conway-Morris A, Lagunes L, Alves J, Alp E, et al. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey. Eur J Clin Microbiol Infect Dis. 2019;38(7):1235–40.CrossRef Rello J, Kalwaje Eshwara V, Conway-Morris A, Lagunes L, Alves J, Alp E, et al. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey. Eur J Clin Microbiol Infect Dis. 2019;38(7):1235–40.CrossRef
26.
go back to reference Lambert ML, Palomar M, Agodi A, Hiesmayr M, Lepape A, Ingenbleek A, et al. Prevention of ventilator-associated pneumonia in intensive care units: an international online survey. Antimicrob Resist Infect Control. 2013;2(1):9.CrossRef Lambert ML, Palomar M, Agodi A, Hiesmayr M, Lepape A, Ingenbleek A, et al. Prevention of ventilator-associated pneumonia in intensive care units: an international online survey. Antimicrob Resist Infect Control. 2013;2(1):9.CrossRef
27.
go back to reference Valencia C, Hammami N, Agodi A, Lepape A, Herrejon EP, Blot S, et al. Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey. Antimicrob Resist Infect Control. 2016;5:49.CrossRef Valencia C, Hammami N, Agodi A, Lepape A, Herrejon EP, Blot S, et al. Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey. Antimicrob Resist Infect Control. 2016;5:49.CrossRef
29.
go back to reference Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. J Clin Microbiol. 2017;55(3):715–23.CrossRef Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. J Clin Microbiol. 2017;55(3):715–23.CrossRef
30.
go back to reference Theuretzbacher U. New drugs - will they solve the problem of resistance to antibiotics? Clin Microbiol Infect. 2017 Oct;23(10):695–6.CrossRef Theuretzbacher U. New drugs - will they solve the problem of resistance to antibiotics? Clin Microbiol Infect. 2017 Oct;23(10):695–6.CrossRef
31.
go back to reference Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704–12.CrossRef Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704–12.CrossRef
32.
go back to reference Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848–55.CrossRef Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848–55.CrossRef
Metadata
Title
European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria
Authors
Alain Lepape
Astrid Jean
Jan De Waele
Arnaud Friggeri
Anne Savey
Philippe Vanhems
Marie Paule Gustin
Dominique L. Monnet
José Garnacho-Montero
Anke Kohlenberg
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-019-0662-8

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.